CRSP+9.54%14.0%
NTLA+22.05%13.0%
BEAM+78.85%11.0%
PRME-4.51%9.0%
VERV0.00%8.0%
CRBU-10.27%6.0%
RCKT-3.57%6.0%
EDIT+11.07%5.0%
MGX-36.27%5.0%
SGMO0.00%5.0%
SRPT-7.07%5.0%
QURE+208.09%4.0%
RGNX+18.98%4.0%
FDMT+123.27%3.0%
MGTX+83.14%2.0%
As of Aug 24, 2026, 4:53 AM ET
Genomics '25: Gene Editing & Genetic Meds Constituents
CRISPR Therapeutics AGCRSP | 14.0% | 2.37% | 10.04% | 27.85% | 23.98% | 13.46% | -1.06% | 74.03% | 22.20% | -52.41% | 9.54% | $5.74B |
Intellia Therapeutics, Inc.NTLA | 13.0% | 3.22% | 6.82% | 19.66% | 20.22% | 42.83% | -6.82% | 75.89% | -45.66% | -91.88% | 22.05% | $1.79B |
Beam Therapeutics Inc.BEAM | 11.0% | 4.83% | 10.84% | 18.57% | 16.61% | 7.36% | 4.57% | 61.04% | 11.00% | -72.05% | 78.85% | $3.06B |
Prime Medicine, Inc.PRME | 9.0% | 4.63% | 3.99% | 14.92% | 16.10% | -2.31% | -26.62% | 89.39% | -23.30% | -77.94% | -4.51% | $612.3M |
Verve Therapeutics, Inc.VERV | 8.0% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 60.36% | 26.92% | -90.36% | 0.00% | $560.0M |
Caribou Biosciences, Inc.CRBU | 6.0% | 3.11% | -1.78% | 5.73% | 13.70% | 4.40% | -12.63% | 92.80% | -24.89% | -94.32% | -10.27% | $164.6M |
Rocket Pharmaceuticals, Inc.RCKT | 6.0% | 0.86% | 0.29% | 10.03% | 12.86% | 0.00% | -29.94% | -44.29% | -81.12% | -88.38% | -3.57% | $383.3M |
Editas Medicine, Inc.EDIT | 5.0% | 5.78% | 5.42% | 19.62% | 20.54% | 51.71% | 41.36% | 163.56% | -19.64% | -95.24% | 11.07% | $477.3M |
Metagenomi, Inc. Common StockMGX | 5.0% | 2.50% | 1.65% | 2.07% | 3.36% | -24.07% | -19.08% | -7.52% | -61.80% | -91.80% | -36.27% | $46.3M |
Sangamo Therapeutics, Inc.SGMO | 5.0% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | $1.80B |
Sarepta Therapeutics, Inc.SRPT | 5.0% | -2.24% | 3.13% | 19.83% | 26.45% | -12.69% | 12.11% | -69.92% | -86.63% | -74.37% | -7.07% | $1.98B |
REGENXBIO Inc.RGNX | 4.0% | -3.07% | 0.66% | 10.17% | 10.63% | -25.56% | 18.58% | 52.06% | -11.62% | -66.25% | 18.98% | $554.2M |
uniQure N.V.QURE | 4.0% | -1.06% | 7.49% | 24.12% | 10.86% | 102.13% | 209.47% | 355.46% | 681.42% | 72.50% | 208.09% | $3.36B |
4D Molecular Therapeutics, Inc.FDMT | 3.0% | -1.68% | 38.01% | 57.20% | 55.50% | 111.07% | 63.87% | 382.62% | 5.82% | -45.30% | 123.27% | $827.5M |
MeiraGTx Holdings plcMGTX | 2.0% | -1.38% | 9.89% | 21.84% | 21.63% | 80.38% | 89.68% | 125.47% | 243.88% | 11.86% | 83.14% | $1.33B |
| Theme return | — | 2.00% | 5.93% | 11.16% | 16.78% | 23.65% | 9.72% | 99.67% | 8.99% | -56.70% | 38.03% | — |
| Average | 6.7% | 1.19% | 6.43% | 16.77% | 16.83% | 23.25% | 22.90% | 94.06% | 42.44% | -57.06% | 32.89% | $1.51B |
| Median | 5.0% | 0.86% | 3.99% | 18.57% | 16.10% | 4.40% | 0.00% | 74.03% | -11.62% | -74.37% | 9.54% | $827.5M |
| Std Dev | 3.5% | 2.71% | 9.33% | 13.81% | 13.00% | 42.65% | 59.18% | 123.11% | 186.16% | 47.15% | 62.17% | $1.49B |
| Min | 2.0% | -3.07% | -1.78% | 0.00% | 0.00% | -25.56% | -29.94% | -69.92% | -86.63% | -95.24% | -36.27% | $46.3M |
| Max | 14.0% | 5.78% | 38.01% | 57.20% | 55.50% | 111.07% | 209.47% | 382.62% | 681.42% | 72.50% | 208.09% | $5.74B |
| % Positive Tickers | 53.33% | 80.00% | 86.67% | 86.67% | 53.33% | 46.67% | 73.33% | 40.00% | 13.33% | 53.33% |
Default: Wgt ↓ · Click headers to sort · Shift+click secondary
About this theme
Genomics '25: Gene Editing & Genetic Meds tracks 15 publicly listed stocks in this theme. Sample tickers: CRSP, NTLA, BEAM, PRME, VERV, CRBU, RCKT, EDIT, MGX, SGMO, SRPT, QURE, and 3 more. Use the table below for the full list.